Drugs / D759
last change Oct 2023 re-read 2 minutes ago

D759

Investigated by
Chong Kun Dang Pharmaceutical

Trials 12 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 112 trials
Phase 1 NCT05928637 Jul → Aug 2023 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05952219 Jun 2023 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Phase 1 NCT05719155 Feb → Mar 2023 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05452525 Jul → Aug 2022 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05347576 Apr → May 2022 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05113693 Nov → Dec 2021 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT04768673 Mar → Apr 2021 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT04706286 Feb → Mar 2021 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Phase 1 NCT04431687 Jun → Jul 2020 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT04260438 Apr → Jun 2020 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as D759 D759 Tab. 1 Tab. and D308 Tab. 1 Tab.(Total 2 Tab.), Single oral administration under fasting condition.” NCT04322032
11

NCT04768673

NCT04260438

NCT05113693

NCT05452525

NCT04246190

NCT05347576

NCT05928637

NCT05719155

NCT04431687

NCT05952219

NCT04706286

Route Oral “Reference drug, CKD-501 1T and D759 1T, QD, PO” NCT04246190